The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia-Reference-Cited by-同舟云学术

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Published:2016-09-15 Issue:11 Volume:128 Page:1525-1528
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhu Hongming¹,Hu Jiong¹,Chen Li¹,Zhou Wei²,Li Xiaoyang¹,Wang Lining¹,Zhao Xia¹,Zhang Yunxiang¹,Zhao Huijin¹,Wang Aihua¹,Chen Yú¹,Sun Huiping¹,Chen Qiusheng¹,Chen Yù¹,Zhao Weili¹,Mi Jianqing¹,Shen Zhixiang¹,Wang Zhenyi¹,Chen Zhu¹,Chen Saijuan¹,Li Junmin¹

Affiliation:

1. Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; and

2. Department of Internal Medicine, Singapore General Hospital, Singapore

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/11/1525/1395369/1525.pdf

Reference20 articles.

1. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.;Shen;Proc Natl Acad Sci USA,2004

2. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.;Hu;Proc Natl Acad Sci USA,2009